Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
2021 | Genome-wide epigenetic landscape of lung adenocarcinoma links HOXB9 DNA methylation to intrinsic EGFR-TKI resistance and heterogeneous responses | SU, SHENG-FANG ; Liu, Chia-Hsin; Cheng, Chiou-Ling; CHAO-CHI HO ; Yang, Tsung-Ying; Chen, Kun-Chieh; Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; HUEI-WEN CHEN ; Chang, Gee-Chen; SUNG-LIANG YU ; Li, Ker-Chau | JCO Precision Oncology | 9 | 6 | |
2021 | The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M | Huang, Yen-Hsiang; Tseng, Jeng-Sen; Hsu, Kuo-Hsuan; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Yang, Tsung-Ying; Chang, Gee-Chen | Scientific reports | 9 | 9 | |
2014 | Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma | Tseng, Jeng-Sen; Wang, Chih-Liang; Huang, Ming-Shyan; CHUNG-YU CHEN ; Chang, Cheng-Yu; Yang, Tsung-Ying; Tsai, Chi-Ren; Chen, Kun-Chieh; Hsu, Kuo-Hsuan; Tsai, Meen-Hsin; SUNG-LIANG YU ; KANG-YI SU ; Wu, Chih-Wei; Yang, Cheng-Ta; Chen, Yuh-Min; MONG-HSUN TSAI | PLoS ONE | 12 | 12 | |
2022 | Influence of the Timing of Leptomeningeal Metastasis on the Outcome of EGFR-Mutant Lung Adenocarcinoma Patients and Predictors of Detectable EGFR Mutations in Cerebrospinal Fluid | Liao, Pei-Ya; Ou, Wei-Fan; KANG-YI SU ; Sun, Ming-Hsi; Huang, Chih-Mei; Chen, Kun-Chieh; Hsu, Kuo-Hsuan; SUNG-LIANG YU ; Huang, Yen-Hsiang; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chang, Gee-Chen | Cancers | 0 | 0 | |
2023 | Low-Dose Computed Tomography Screening in Relatives With a Family History of Lung Cancer | Wang, Chi-Liang; Hsu, Kuo-Hsuan; Chang, Ya-Hsuan; CHAO-CHI HO ; CHUN-JU CHIANG ; Chen, Kun-Chieh; Cheung, Yun-Chung; Huang, Pei-Ching; Chen, Yu-Ruei; Chen, Chih-Yi ; Hsu, Chung-Ping; Hsia, Jiun-Yi; Chen, Hsuan-Yu; Yang, Shi-Yi; Li, Yao-Jen; Yang, Tsung-Ying; Tseng, Jeng-Sen; Chuang, Cheng-Yen; Hsiung, Chao A; Chen, Yuh-Min; Huang, Ming-Shyan; CHONG-JEN YU ; KUAN-YU CHEN ; Su, Wu-Chou; Chen, Jeremy J W; SUNG-LIANG YU ; Chen, Chien-Jen; PAN-CHYR YANG ; Tsai, Ying-Huang; Chang, Gee-Chen | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2 | 0 | |
2024 | Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study | Chang, Gee-Chen; Chiu, Chao-Hua; CHONG-JEN YU ; YEUN-CHUNG CHANG ; Chang, Ya-Hsuan; Hsu, Kuo-Hsuan; Wu, Yu-Chung; CHIH-YI CHEN ; Hsu, Hsian-He; Wu, Ming-Ting; Yang, Cheng-Ta; Chong, Inn-Wen; Lin, Yu-Ching; Hsia, Te-Chun; Lin, Meng-Chih; Su, Wu-Chou; Lin, Chih-Bin; Lee, Kang-Yun; Wei, Yu-Feng; Lan, Gong-Yau; Chan, Wing P; Wang, Kao-Lun; Wu, Mei-Han; Tsai, Hao-Hung; Chian, Chih-Feng; Lai, Ruay-Sheng; JIN-YUAN SHIH ; Wang, Chi-Liang; Hsu, Jui-Sheng; Chen, Kun-Chieh; Chen, Chun-Ku; Hsia, Jiun-Yi; Peng, Chung-Kan; Tang, En-Kuei; CHIA-LIN HSU ; Chou, Teh-Ying; Shen, Wei-Chih; Tsai, Ying-Huang; Tsai, Chun-Ming; Chen, Yuh-Min; Lee, Yu-Chin; Chen, Hsuan-Yu; SUNG-LIANG YU ; Chen, Chien-Jen; Wan, Yung-Liang; Hsiung, Chao Agnes; PAN-CHYR YANG | The Lancet. Respiratory medicine | 6 | | |
2022 | PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients | Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Huang, Yen-Hsiang; Chang, Gee-Chen | Scientific reports | 11 | 9 | |
2024 | Primary tumor consolidative therapy improves the outcomes of patients with advanced EGFR-mutant lung adenocarcinoma treated with first-line osimertinib | Wu, Jia-Jun; Tseng, Jeng-Sen; Zheng, Zhe-Rong; Chu, Cheng-Hsiang; Chen, Kun-Chieh; MONG-WEI LIN ; Huang, Yen-Hsiang; Hsu, Kuo-Hsuan; Yang, Tsung-Ying; SUNG-LIANG YU ; JIN-SHING CHEN ; CHAO-CHI HO ; Chang, Gee-Chen | Therapeutic advances in medical oncology | 0 | | |
2021 | Primary Tumor Radiotherapy During EGFR-TKI Disease Control Improves Survival of Treatment Naïve Advanced EGFR-Mutant Lung Adenocarcinoma Patients | Hsu, Kuo-Hsuan; Huang, Jing-Wen; Tseng, Jeng-Sen; Chen, Kuan-Wen; Weng, Yih-Chyang; SUNG-LIANG YU ; Yang, Tsung-Ying; Huang, Yen-Hsiang; Chen, Jeremy J W; Chen, Kun-Chieh; Chang, Gee-Chen | OncoTargets and therapy | 7 | 6 | |
2021 | Primary Tumor Resection Is Associated with a Better Outcome among Advanced EGFR-Mutant Lung Adenocarcinoma Patients Receiving EGFR-TKI Treatment | Tseng, Jeng-Sen; Hsu, Kuo-Hsuan; Zheng, Zhe-Rong; Yang, Tsung-Ying; Chen, Kun-Chieh; Huang, Yen-Hsiang; KANG-YI SU ; SUNG-LIANG YU ; Chang, Gee-Chen | Oncology | 9 | 9 | |
2014 | Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma | Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; Hsu, Kuo-Hsuan; CHONG-JEN YU ; WEI-YU LIAO ; Tsai, Chi-Ren; Tsai, Meen-Hsin; SUNG-LIANG YU ; KANG-YI SU ; Chen, Jeremy Jw; Chen, Hsuan-Yu; MONG-HSUN TSAI | OncoTargets and Therapy | 15 | 14 | |
2021 | Publisher Correction: The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M | Huang, Yen-Hsiang; Tseng, Jeng-Sen; Hsu, Kuo-Hsuan; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Yang, Tsung-Ying; Chang, Gee-Chen | Scientific reports | 0 | 0 | |
2021 | The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 study | Huang, Yen-Hsiang; Hung, Jen-Yu; Ko, How-Wen; Su, Po-Lan; Lai, Chun-Liang; Chang, Huang-Chih; Hsia, Te-Chun; Lin, Sheng-Hao; Wu, Kuan-Li; Yang, Cheng-Ta; Su, Wu-Chou; Chu, Yi-Chun; Wang, Chin-Chou; WEI-YU LIAO ; YEN-TING LIN ; Lin, Ching-Hsiung; Lin, Meng-Chih; Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; Lee, Mei-Hsuan; SUNG-LIANG YU ; CHAO-CHI HO ; Chang, Gee-Chen | Therapeutic advances in medical oncology | 3 | 2 | |
2022 | Various impacts of driver mutations on the PD-L1 expression of NSCLC | Chu, Cheng-Hsiang; Huang, Yen-Hsiang; Lee, Po-Hsin; Hsu, Kuo-Hsuan; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chang, Gee-Chen | PloS one | 3 | 1 | |